Skip to main content

Advertisement

SpringerLink
Log in

A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Conversion surgery for initially unresectable hepatocellular carcinoma appears to be increasing in incidence since the advent of new molecular target drugs and immune checkpoint inhibitors; however, reports on long-term outcomes are limited and the prognostic relevance of this treatment strategy remains unclear. Herein, we report the case of a 75-year-old man with hepatocellular carcinoma, 108 mm in diameter, accompanied by a tumor thrombus in the middle hepatic vein that extended to the right atrium via the suprahepatic vena cava. He underwent conversion surgery after preceding lenvatinib treatment and is alive without disease 51 months after the commencement of treatment and 32 months after surgery. Just before conversion surgery, after 19 months of lenvatinib treatment, the main tumor had reduced in size to 72 mm in diameter, the tip of the tumor thrombus had receded back to the suprahepatic vena cava, and the tumor thrombus vascularity was markedly reduced. The operative procedure was an extended left hepatectomy with concomitant middle hepatic vein resection. The tumor thrombus was removed under total vascular exclusion via incision of the root of the middle hepatic vein. Histopathological examination revealed that more than half of the liver tumor and the tumor thrombus were necrotic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Faber W, Stockmann M, Kruschke JE, et al. Implication of microscopic and macroscopic vascular invasion for liver resection in patients with hepatocellular carcinoma. Dig Surg. 2014;31:204–9.

    Article  PubMed  Google Scholar 

  2. Zhong JH, Rodríguez AC, Ke Y, et al. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore). 2015;94: e396.

    Article  CAS  PubMed  Google Scholar 

  3. Cortese S, Morales J, Martín L, et al. Hepatic resection with thrombectomy in the treatment of hepatocellular carcinoma associated with macrovascular invasion. Cir Esp (Engl Ed). 2020;98:9–17.

    Article  PubMed  Google Scholar 

  4. Wang Y, Yuan L, Ge RL, et al. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20:914–22.

    Article  PubMed  Google Scholar 

  5. Kokudo T, Hasegawa K, Matsuyama Y, Liver Cancer Study Group of Japan, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510–7.

    Article  CAS  PubMed  Google Scholar 

  6. Kasai Y, Hatano E, Seo S, et al. Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy. Surgery. 2017;162:742–51.

    Article  PubMed  Google Scholar 

  7. Ichida A, Kokudo T, Shimada S, et al. Liver resection for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium: a large-scale multicenter survey conducted in Japan. Ann Surg. 2023;278:e549–55.

    Article  PubMed  Google Scholar 

  8. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

    Article  PubMed  Google Scholar 

  9. Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541–65.

    Article  PubMed  Google Scholar 

  10. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  PubMed  Google Scholar 

  11. Finn RS, Qin S, Ikeda M, IMbrave150 Investigators, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  PubMed  Google Scholar 

  12. Sato N, Beppu T, Kinoshita K, et al. Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy. Anticancer Res. 2019;39:5695–701.

    Article  PubMed  Google Scholar 

  13. Matsuki R, Kawai K, Suzuki Y, et al. Pathological complete response in conversion hepatectomy induced by lenvatinib for advanced hepatocellular carcinoma. Liver Cancer. 2020;9:358–60.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine (Baltimore). 2020;99: e22782.

    Article  PubMed  Google Scholar 

  15. Ohya Y, Hayashida S, Tsuji A, et al. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy. Surg Case Rep. 2020;6:318.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Yokoo H, Takahashi H, Hagiwara M, et al. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: a case report. World J Hepatol. 2020;12:1349–57.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Matsuki R, Okano N, Arai T, et al. Regression of tumor thrombus in the suprahepatic vena cava of hepatocellular carcinoma and conversion hepatectomy induced by lenvatinib. Liver Cancer. 2021;11:278–80.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Takahashi K, Kim J, Takahashi A, et al. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: a case report. World J Hepatol. 2021;13:384–92.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Endo K, Kuroda H, Abe T, et al. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization. Hepatol Res. 2021;51:1082–6.

    Article  PubMed  Google Scholar 

  20. Sugimoto R, Inada H, Tanaka Y, et al. Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma. Clin J Gastroenterol. 2021;14:1484–90.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Shiozaki H, Furukawa K, Haruki K, et al. A multidisciplinary treatment strategy with conversion surgery for hepatocellular carcinoma. Anticancer Res. 2023;43:1761–6.

    Article  CAS  PubMed  Google Scholar 

  22. Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28:7663–72.

    Article  PubMed  Google Scholar 

  23. Shindoh J, Kawamura Y, Kobayashi M, et al. Prognostic advantages of individual additional interventions after lenvatinib therapy in patients with advanced hepatocellular carcinoma. J Gastrointest Surg. 2022;26:1637–46.

    Article  PubMed  Google Scholar 

  24. Itoh S, Toshida K, Morita K, et al. Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. Int J Clin Oncol. 2022;27:1725–32.

    Article  CAS  PubMed  Google Scholar 

  25. Hidaka M, Hara T, Soyama A, et al. The outcome of conversion liver resection surgery by lenvatinib treatment: a single center experience. Anticancer Res. 2022;42:3049–54.

    Article  PubMed  Google Scholar 

  26. Yano S, Kawaoka T, Johira Y, et al. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. Medicine (Baltimore). 2021;100: e27576.

    Article  PubMed  Google Scholar 

  27. Hidaka Y, Tomita M, Desaki R, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20:228.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hoshino T, Naganuma A, Furusawa A, et al. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol. 2022;15:776–83.

    Article  PubMed  Google Scholar 

  29. Miyata T, Sugi K, Horino T, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43:943–7.

    Article  PubMed  Google Scholar 

  30. Fukunaga A, Takata K, Itoh S, et al. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol. 2023;16:224–8.

    Article  PubMed  Google Scholar 

  31. Tsunemitsu R, Tabuchi M, Sakamoto S, et al. Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy. Surg Case Rep. 2023;9:93.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kurisaki K, Soyama A, Hara T, et al. Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg. 2023;40:84–9.

    Article  CAS  PubMed  Google Scholar 

  33. Shimose S, Iwamoto H, Shirono T, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12:12325–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hiraoka A, Kumada T, Tsuji K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2019;8:121–9.

    Article  PubMed  Google Scholar 

  35. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

    Article  CAS  PubMed  Google Scholar 

  36. Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304.

    Article  CAS  PubMed  Google Scholar 

  37. Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112–9.

    Article  Google Scholar 

  38. Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. J Cancer Med. 2018;7:2641–53.

    Article  CAS  Google Scholar 

  39. Hasegawa K, Takemura N, Yamashita T, Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383–90.

    Article  PubMed  Google Scholar 

  40. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779–86.

    Article  CAS  PubMed  Google Scholar 

  41. Dubbelman AC, Rosing H, Nijenhuis C, et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs. 2015;33:233–40.

    Article  CAS  PubMed  Google Scholar 

  42. Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161–70.

    CAS  PubMed  Google Scholar 

  43. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12:16–22.

    Article  PubMed  Google Scholar 

  44. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res. 2009;39:107–16.

    Article  PubMed  Google Scholar 

  45. Okuno M, Ishii T, Ichida A, et al. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab. BMC Cancer. 2023;23:780.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors have no source of funding for this study.

Author information

Authors and Affiliations

  1. Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan

    Yu Gyoda, Hirofumi Ichida, Fumihiro Kawano, Yoshinori Takeda, Ryuji Yoshioka, Hiroshi Imamura, Yoshihiro Mise & Akio Saiura

  2. Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan

    Yuki Fukumura

Authors
  1. Yu Gyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirofumi Ichida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumihiro Kawano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuji Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Mise
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuki Fukumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akio Saiura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Writing—original draft preparation: YG; conceptualization: FK, YT, RY, HI, YM, YF; writing—review and editing: HI, AS; supervision: AS.

Corresponding author

Correspondence to Akio Saiura.

Ethics declarations

Conflict of interest

The authors have no competing interests.

Ethics approval and consent to participate

The authors obtained informed consent from the patient for the course of treatment.

Consent for publication

The authors obtained informed consent from the patient for publication of this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gyoda, Y., Ichida, H., Kawano, F. et al. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report. Clin J Gastroenterol 17, 311–318 (2024). https://doi.org/10.1007/s12328-023-01909-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-023-01909-4

Keywords

Search

Navigation